Tempus AI, a Chicago firm that leverages AI for personalized disease prevention and therapy, is acquiring Personalis, a Fremont, California-based cancer-testing company. The total value including debt is $1.5 billion.
The $16.25 per share acquisition price is a 5.6 percent premium over where Personalis stock closed the Friday before the announcement. The two companies have been working together under an existing partnership since late 2023.
Tempus stock fell to $47.65 in New York. Personalis shares fell as much as 15 percent to $13.15.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
Bloomberg Intelligence analyst Jonathan Palmer said, "The strategic rationale is clear" for the deal. He noted that the existing arrangement between the firms was scheduled to last until 2029.
An increasing number of firms are seeking to apply AI in clinical and healthcare research contexts - ranging from accelerating drug development to interpreting medical images and aiding physicians in diagnosis. In 2025, general-purpose AI companies OpenAI and Anthropic introduced healthcare-specific editions of their well-known chatbots, offering capabilities like medical case reasoning and assistance with biological research.
The acquisition underscores the accelerating integration of artificial intelligence into oncology. Tempus AI, founded in 2015, has built a large repository of clinical and molecular data to power its AI algorithms for personalized medicine. Personalis specializes in advanced genomic testing for cancer, including liquid biopsies and tumor profiling.
Tempus, which went public in 2024, has been aggressively expanding its data-driven approach to oncology. The company's platform analyzes de-identified clinical and molecular data to help healthcare providers make more informed treatment decisions. Personalis, meanwhile, has developed proprietary liquid biopsy and whole-exome sequencing technologies that detect minimal residual disease and track tumor evolution. The integration of these capabilities could create a comprehensive AI-powered cancer diagnostics and treatment planning system.
Tempus, founded by Eric Lefkofsky in 2015, has steadily grown its database of de-identified patient records and genomic information. Personalis's NeXT Personal liquid biopsy test is already used by oncologists to monitor cancer recurrence. Combining these assets could allow Tempus to offer end-to-end AI-driven cancer care, from early detection through treatment monitoring.
By fully absorbing Personalis, Tempus can deepen its access to genomic data and potentially accelerate the development of AI-driven diagnostic tools. The deal also reflects a broader push by AI companies into healthcare; OpenAI and Anthropic have released chatbots tailored for medical use, while many startups are applying machine learning to drug discovery and clinical decision support.
Tempus's existing 12.5% stake gave it insight into Personalis's operations, likely smoothing the acquisition process. The transaction's long timeline - closing in late 2026 or early 2027 - suggests regulatory and integration hurdles that the companies will navigate over the next two years.
The growing convergence of artificial intelligence and genomics is reshaping oncology. Tempus's platform already leverages deep learning to match patients with clinical trials and predict treatment responses. By folding in Personalis's highly sensitive liquid biopsy assays, the combined entity could advance the early detection of recurrence and enable more dynamic treatment adjustments, giving oncologists a real-time view of how a tumor evolves under therapy.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
